Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative ...

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...

Alumis (ALMS) announced positive 52-week data from the open-label extension, OLE, of its Phase 2 STRIDE clinical trial evaluating ESK-001 in patients with moderate-to-severe plaque psoriasis. The ...

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price target of $19.00. The company’s shares opened ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. ESK-001, a tyrosine kinase 2 inhibitor, may be a ...

After hours: March 13 at 4:05:05 PM EDT Loading Chart for SLRN ...

Addressing Limitations of Current Pain Treatments Current treatment options for localized neuropathic and inflammatory pain-including NSAIDs, lidocaine patches, capsaicin creams, gabapentin, ...

Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...